search
Back to results

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

Primary Purpose

Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
KT-474/Placebo
KT-474
Sponsored by
Kymera Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Healthy Volunteer focused on measuring Atopic Dermatitis, Hidradenitis Suppurativa, Immune-inflammatory diseases

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Healthy Volunteer (Parts A and B) Inclusion Criteria:

  1. Male and female subjects, including female subjects of child bearing potential, between the ages of 18 and 55 with a weight at least 50 kg and a body mass index (BMI) between 18.0 and 30.0 kg/m2.
  2. Subjects confirmed as negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection test at Screening and on Day -2.
  3. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
  4. Agreement and ability to comply with all contraception requirements if applicable.
  5. All subjects must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Healthy Volunteer (Parts A and B) Exclusion Criteria:

  1. Evidence or history of a clinically significant medical condition or other condition that might significantly interfere with the absorption, distribution, metabolism, or excretion of study drug, or place the subject at an unacceptable risk as a participant in this study.
  2. Healthy volunteers who have a clinically relevant history or presence of respiratory, GI, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, or connective tissue diseases or disorders.
  3. Healthy volunteers who have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease.
  4. Female Healthy volunteers who are pregnant, trying to become pregnant or lactating or breastfeeding.
  5. Healthy volunteers who have participated in any investigational drug or device clinical study within 3 months prior to first dosing on this study.
  6. Healthy volunteers who have previously participated in a study with an investigational product or device involving the dosing of a biological targeted at any immune pathway within 1 year prior to Screening.

AD or HS Patient (Part C) Inclusion Criteria:

  1. Male or female patients aged 18 years to 55 years (inclusive) at the time of Screening, and in generally good health, except for AD or HS, and has a BMI of 17.5 to 35.0 kg/m2; and a total body weight >50 kg (110 lb).
  2. Diagnosis of AD or HS for at least 6 months.
  3. Patients with AD: having at least 10% treatable percentage body surface area at Screening or on Admission (excluding the scalp and designated venous access areas).
  4. Willingness and ability to comply with all contraception requirements as applicable based on reproductive status.
  5. Has adequate venous access with venous access sites having AD-unaffected, non-infected skin to permit repeated PK sampling.
  6. Female patients must have a negative result for the serum pregnancy test at the Screening Visit and on admission.
  7. Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.
  8. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  9. Patients with HS: A total Abscess and Inflammatory Nodule count of ≥4 at baseline

AD or HS Patient (Parts C) Exclusion Criteria:

  1. Has any clinically significant medical disorder, condition, disease (including active or potentially recurrent dermatological conditions other than AD or HS), significant physical examination or laboratory findings that may interfere with study objectives, in the Investigator's opinion (eg, conditions or findings that may expose a patient to unacceptable risk by study participation, confound the evaluation of treatment response or adverse events, or otherwise interfere with a patient's ability to complete the study).
  2. Has an active systemic or soft tissue infection, including known actively-infected AD or HS skin lesion.
  3. Treatment with an investigational product within 30 days or 5 half-lives preceding the first dose of investigational product (whichever is longer).
  4. Use of prescription or nonprescription drugs including topical corticosteroids, vitaminic and dietary supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product.
  5. Blood donation (excluding plasma donations and platelet donations) of approximately ≥400 mL within 3 months or ≥200 mL within a month prior to dosing.
  6. History of sensitivity to heparin or heparin-induced thrombocytopenia.
  7. Unwilling or unable to comply with the protocol procedures and/or assessments.
  8. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
  9. Patients with HS: Fistula and Tunnel count of >20 at baseline.
  10. Patients with AD: Active herpes infection or history of eczema herpeticum.

Sites / Locations

  • Medical Dermatology Specialists
  • Southwest Skin Specialists 32nd St
  • Southwest Skin Specialists Tatum
  • Beatrice Keller Clinic
  • Encore Medical Research, LLC. - Boynton Beach
  • Research Centers of America
  • Encore Medical Research, LLC. - Hollywood
  • Encore Medical Research, LLC. - Weston
  • Dermatology and Skin Cancer Center of Leawood
  • Dermatology and Skin Cancer Center of Overland Park
  • Dermatology and Skin Cancer Center of Lee's Summit
  • TKL Research
  • U.S. Dermatology Partners Jollyville
  • U.S. Dermatology Partners Cedar Park

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Single ascending dose cohorts in healthy subjects

Multiple ascending dose cohorts in healthy subjects

Food Effect Cohort in healthy subjects

Multiple dose cohort in HS and AD patients

Multiple dose cohorts in healthy subjects

Arm Description

Healthy volunteer subject cohorts randomized 6:2 receiving a single dose of KT-474 or placebo. The first cohort will receive 25 mg of KT-474 or placebo. Dose escalation will occur if KT-474 or placebo is tolerated.

Healthy volunteer subject cohorts randomized 9:3 to receive KT-474 or placebo for 14 days continuous dosing. The first cohort will receive a dose of KT-474 or placebo determined to be safe based on data generated in the SAD portion.

Healthy Volunteer SAD subject cohorts (up to 5) will receive a single dose of KT-474 in the fed state.

A single cohort of up to 30 patients with AD or HS to receive a dose of KT-474 determined to be safe based on data generated in the healthy volunteer MAD portion, dosed daily X 28 days.

Healthy volunteer subject cohorts randomized 9:3 to receive KT-474 or placebo every other day over 14 days, and/or twice weekly over 15 days. The first cohort will receive a dose of KT-474 or placebo determined to be safe based on data generated in the SAD and MAD portion.

Outcomes

Primary Outcome Measures

Incidence and severity of treatment emergent Adverse Events
Incidence and frequency of use of concomitant medication

Secondary Outcome Measures

Area under the curve plasma concentration from time zero to infinity [AUC(0-∞)] (single dose only)
Area under the curve plasma concentration from time zero to last measurable concentration [AUC(0-last)]
Area under the plasma concentration-time curve during a dosing interval [AUC(0-tau)]
Maximum observed plasma concentration (Cmax)
Time to maximum observed plasma concentration (Tmax)
Apparent clearance (CL/F)
Apparent volume of distribution (Vz/F)
Terminal elimination half-life (t1/2)
Mean residence time (MRT)
Renal clearance (CLR)

Full Information

First Posted
February 12, 2021
Last Updated
October 21, 2022
Sponsor
Kymera Therapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04772885
Brief Title
A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)
Official Title
A Phase 1 Randomized, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Completed
Study Start Date
February 23, 2021 (Actual)
Primary Completion Date
October 20, 2022 (Actual)
Study Completion Date
October 20, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kymera Therapeutics, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
KT-474 is an oral heterobifunctional small molecule IRAK4 degrader being developed for the treatment of interleukin-1 receptor (IL-1R)/toll-like receptor (TLR)-driven immune-inflammatory diseases. This first-in-human (FIH) study will characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of a single ascending dose and multiple ascending doses of KT-474 in healthy volunteers and patients with atopic dermatitis (AD) or hidradenitis suppurativa (HS). The effects of food on the absorption of KT-474 will also be evaluated in healthy volunteers.
Detailed Description
This is a first-in-human (FIH), Phase 1 randomized, placebo-controlled, single and multiple ascending dose trial of KT-474 that will characterize the safety, PK and PD of orally administered KT-474 after a single dose (Part A) and after repeated dosing first in healthy adult volunteers (Part B) and then in patients with AD or HS (Part C). Initially, a dose range of KT-474 in single ascending dose (SAD) escalation cohorts will be explored in healthy subjects. Up to five single dose cohorts of healthy subjects is also planned to understand food effects (FE) on the PK of KT-474. Enrollment of healthy subjects into 2-week multiple ascending dose (MAD) escalation cohorts will be initiated once sufficient safety and PK data from multiple SAD cohorts are available to inform the safe starting dose for the 2-week MAD portion of the study. After the MAD portion in healthy subjects is completed, the safety, PK, and PD of a dose of KT-474 that was found to be safe in healthy subjects when administered for 2 weeks will then be evaluated in AD or HS subjects for 28 days of dosing. Separately, additional multiple dose cohorts evaluating once every other day and/or twice weekly dosing schedules at or below previously evaluated dose levels in healthy volunteers may be initiated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Keywords
Atopic Dermatitis, Hidradenitis Suppurativa, Immune-inflammatory diseases

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Model Description
Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
randomized double blind (for Parts A and B only)
Allocation
Randomized
Enrollment
154 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Single ascending dose cohorts in healthy subjects
Arm Type
Experimental
Arm Description
Healthy volunteer subject cohorts randomized 6:2 receiving a single dose of KT-474 or placebo. The first cohort will receive 25 mg of KT-474 or placebo. Dose escalation will occur if KT-474 or placebo is tolerated.
Arm Title
Multiple ascending dose cohorts in healthy subjects
Arm Type
Experimental
Arm Description
Healthy volunteer subject cohorts randomized 9:3 to receive KT-474 or placebo for 14 days continuous dosing. The first cohort will receive a dose of KT-474 or placebo determined to be safe based on data generated in the SAD portion.
Arm Title
Food Effect Cohort in healthy subjects
Arm Type
Experimental
Arm Description
Healthy Volunteer SAD subject cohorts (up to 5) will receive a single dose of KT-474 in the fed state.
Arm Title
Multiple dose cohort in HS and AD patients
Arm Type
Experimental
Arm Description
A single cohort of up to 30 patients with AD or HS to receive a dose of KT-474 determined to be safe based on data generated in the healthy volunteer MAD portion, dosed daily X 28 days.
Arm Title
Multiple dose cohorts in healthy subjects
Arm Type
Experimental
Arm Description
Healthy volunteer subject cohorts randomized 9:3 to receive KT-474 or placebo every other day over 14 days, and/or twice weekly over 15 days. The first cohort will receive a dose of KT-474 or placebo determined to be safe based on data generated in the SAD and MAD portion.
Intervention Type
Drug
Intervention Name(s)
KT-474/Placebo
Intervention Description
KT-474 or matching placebo oral tablet(s)
Intervention Type
Drug
Intervention Name(s)
KT-474
Intervention Description
KT-474 oral tablet(s)
Primary Outcome Measure Information:
Title
Incidence and severity of treatment emergent Adverse Events
Time Frame
up to 28 days
Title
Incidence and frequency of use of concomitant medication
Time Frame
up to 28 days
Secondary Outcome Measure Information:
Title
Area under the curve plasma concentration from time zero to infinity [AUC(0-∞)] (single dose only)
Time Frame
up to 28 days
Title
Area under the curve plasma concentration from time zero to last measurable concentration [AUC(0-last)]
Time Frame
up to 28 days
Title
Area under the plasma concentration-time curve during a dosing interval [AUC(0-tau)]
Time Frame
up to 28 days
Title
Maximum observed plasma concentration (Cmax)
Time Frame
up to 28 days
Title
Time to maximum observed plasma concentration (Tmax)
Time Frame
up to 28 days
Title
Apparent clearance (CL/F)
Time Frame
up to 28 days
Title
Apparent volume of distribution (Vz/F)
Time Frame
up to 28 days
Title
Terminal elimination half-life (t1/2)
Time Frame
up to 28 days
Title
Mean residence time (MRT)
Time Frame
up to 28 days
Title
Renal clearance (CLR)
Time Frame
up to 28 days
Other Pre-specified Outcome Measures:
Title
IRAK4 levels in peripheral blood mononuclear cells
Time Frame
up to 28 days
Title
IRAK4 levels in skin
Time Frame
up to 28 days
Title
Percentage Change from baseline in Total Abscess and Inflammatory Nodule (AN) Count, Skin Pain Numerical Rating Scale (NRS), Peak pruritis NRS, and HS Physician's Global Assessment (HS-PGA) in HS patients
Time Frame
up to 42 days
Title
Percentage Change from baseline in Eczema Area and Severity Index (EASI), Peak Pruritus Numerical Rating Scale (NRS) and Investigator Global Assessment (IGA) in AD patients
Time Frame
up to 42 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Healthy Volunteer (Parts A and B) Inclusion Criteria: Male and female subjects, including female subjects of child bearing potential, between the ages of 18 and 55 with a weight at least 50 kg and a body mass index (BMI) between 18.0 and 30.0 kg/m2. Subjects confirmed as negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection test at Screening and on Day -2. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study. Agreement and ability to comply with all contraception requirements if applicable. All subjects must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Healthy Volunteer (Parts A and B) Exclusion Criteria: Evidence or history of a clinically significant medical condition or other condition that might significantly interfere with the absorption, distribution, metabolism, or excretion of study drug, or place the subject at an unacceptable risk as a participant in this study. Healthy volunteers who have a clinically relevant history or presence of respiratory, GI, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, or connective tissue diseases or disorders. Healthy volunteers who have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease. Female Healthy volunteers who are pregnant, trying to become pregnant or lactating or breastfeeding. Healthy volunteers who have participated in any investigational drug or device clinical study within 3 months prior to first dosing on this study. Healthy volunteers who have previously participated in a study with an investigational product or device involving the dosing of a biological targeted at any immune pathway within 1 year prior to Screening. AD or HS Patient (Part C) Inclusion Criteria: Male or female patients aged 18 years to 55 years (inclusive) at the time of Screening, and in generally good health, except for AD or HS, and has a BMI of 17.5 to 35.0 kg/m2; and a total body weight >50 kg (110 lb). Diagnosis of AD or HS for at least 6 months. Patients with AD: having at least 10% treatable percentage body surface area at Screening or on Admission (excluding the scalp and designated venous access areas). Willingness and ability to comply with all contraception requirements as applicable based on reproductive status. Has adequate venous access with venous access sites having AD-unaffected, non-infected skin to permit repeated PK sampling. Female patients must have a negative result for the serum pregnancy test at the Screening Visit and on admission. Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Patients with HS: A total Abscess and Inflammatory Nodule count of ≥4 at baseline AD or HS Patient (Parts C) Exclusion Criteria: Has any clinically significant medical disorder, condition, disease (including active or potentially recurrent dermatological conditions other than AD or HS), significant physical examination or laboratory findings that may interfere with study objectives, in the Investigator's opinion (eg, conditions or findings that may expose a patient to unacceptable risk by study participation, confound the evaluation of treatment response or adverse events, or otherwise interfere with a patient's ability to complete the study). Has an active systemic or soft tissue infection, including known actively-infected AD or HS skin lesion. Treatment with an investigational product within 30 days or 5 half-lives preceding the first dose of investigational product (whichever is longer). Use of prescription or nonprescription drugs including topical corticosteroids, vitaminic and dietary supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product. Blood donation (excluding plasma donations and platelet donations) of approximately ≥400 mL within 3 months or ≥200 mL within a month prior to dosing. History of sensitivity to heparin or heparin-induced thrombocytopenia. Unwilling or unable to comply with the protocol procedures and/or assessments. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study. Patients with HS: Fistula and Tunnel count of >20 at baseline. Patients with AD: Active herpes infection or history of eczema herpeticum.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ashwin Gollerkeri, MD
Organizational Affiliation
Kymera Therapeutics, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Medical Dermatology Specialists
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85006
Country
United States
Facility Name
Southwest Skin Specialists 32nd St
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85018
Country
United States
Facility Name
Southwest Skin Specialists Tatum
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85028
Country
United States
Facility Name
Beatrice Keller Clinic
City
Sun City West
State/Province
Arizona
ZIP/Postal Code
85375
Country
United States
Facility Name
Encore Medical Research, LLC. - Boynton Beach
City
Boynton Beach
State/Province
Florida
ZIP/Postal Code
33436
Country
United States
Facility Name
Research Centers of America
City
Hollywood
State/Province
Florida
ZIP/Postal Code
22024
Country
United States
Facility Name
Encore Medical Research, LLC. - Hollywood
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33021
Country
United States
Facility Name
Encore Medical Research, LLC. - Weston
City
Weston
State/Province
Florida
ZIP/Postal Code
33331
Country
United States
Facility Name
Dermatology and Skin Cancer Center of Leawood
City
Leawood
State/Province
Kansas
ZIP/Postal Code
66211
Country
United States
Facility Name
Dermatology and Skin Cancer Center of Overland Park
City
Overland Park
State/Province
Kansas
ZIP/Postal Code
66223
Country
United States
Facility Name
Dermatology and Skin Cancer Center of Lee's Summit
City
Lee's Summit
State/Province
Missouri
ZIP/Postal Code
64064
Country
United States
Facility Name
TKL Research
City
Fair Lawn
State/Province
New Jersey
ZIP/Postal Code
07410
Country
United States
Facility Name
U.S. Dermatology Partners Jollyville
City
Austin
State/Province
Texas
ZIP/Postal Code
78759
Country
United States
Facility Name
U.S. Dermatology Partners Cedar Park
City
Cedar Park
State/Province
Texas
ZIP/Postal Code
78613
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

We'll reach out to this number within 24 hrs